Voiding Dysfunction Clinical Trial
Official title:
Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study
Up to 50% of patients undergoing pelvic floor repair experience short-term postoperative
voiding dysfunction, increasing the length of hospitalization, cost and anxiety among
patients.
The mechanism behind this problem is the sutures placed in the pubocervical fascia during
the cystocele repair. The cited benefit of bladder plication is greater cure of cystocele.
The existence of pubocervical fascia and the need for placement of plicating sutures over
the bladder have been questioned.
The objective of this study is to determine if avoiding cystocele plication in women
undergoing surgery for cystocele decreases the need of catheterization beyond post operative
day #2.
We will conduct a RCT of patients undergoing transvaginal repair of midline cystocele at the
Mount Sinai Hospital. Patients will be randomized to receiving plicating sutures versus no
plication. This procedure may be conducted with or without concomitant correction of other
sites of prolapse. However, they will not have any procedures for correction of stress
incontinence.
This study will be powered to detect a reduction in voiding dysfunction from 50% to 25% of
patients. Using a χ2 distribution, and an alpha error of 0.05, the required sample size is
58 patients per group.
Vaginal prolapse is a common problem in women. Approximately 11% of women undergo pelvic
reconstructive surgery for either pelvic organ prolapse and/or urinary incontinence[1].
Several surgical techniques for correction of prolapse have evolved and have been
scientifically evaluated. However, many basic surgical gynecological principles and
techniques have been passed on over generations without any scientific evaluation. The
technique of transvaginal repair of cystocele due to an anterior midline defect has
traditionally included four steps: 1. mobilization of the defect (i.e. separation of vagina
from bladder); 2. reduction of the defect (i.e. placement of plicating sutures into the
pubocervical fascia); 3. trimming of redundant vaginal tissues; and 4. reapproximating the
vaginal mucosa[2, 3]. Although each surgeon may modify any of these steps (ex. Depth of
dissection, location and number of sutures), the principles are consistent. The existence of
pubocervical fascia and the need for placement of plicating sutures over the bladder have
been questioned, and some vaginal surgeons omit this step[4-6]. The cited benefit of bladder
plication is greater cure of cystocele. Some of the potential risks of plication include
ureteric obstruction, if the sutures are near the ureteric orifice, and voiding dysfunction
if the sutures are near the urethrovesical junction[3, 7]. A chart review of patients at the
Mount Sinai Hospital, who underwent typical pelvic floor repair, including transvaginal
cystocele repair and mid-urethral sling, has shown that approximately 50% of patients
experience short-term postoperative voiding dysfunction (non-published data), increasing the
length of hospitalization, cost and anxiety among patients.
This pilot trial will assess the short-term risks of cystocele plication, and will assess
trial feasibility. Ideally a larger subsequent trial will assess the cure of cystocele one
year after surgery. To the best of my knowledge, this is the first study to assess the
short-term post-operative outcomes in women who undergo this procedure.
3- Research Question In women with cystocele due to an anterior midline defect, does
cystocele plication (independent variable) result in more or less patients requiring
catheterization beyond postoperative day 2 (dependent variable) compared to no plication?
Hypothesis The hypothesis is that there may be more short-term voiding dysfunction and
ureteric obstruction following cystocele repair with plication than following cystocele
repair without plication.
4- Population of Interest and Sampling Methods Inclusion criteria: Patients between 18 and
75 years, who will undergo surgery at the Mount Sinai Hospital that includes cystocele
repair, will be eligible.
Exclusion criteria: Patients will be excluded if the surgeon places anterior vaginal mesh or
a mid-urethral sling, and/or if they had prior surgery for anterior vaginal wall prolapse
and/or stress urinary incontinence.
Recruitment strategy: The patients will be recruited at the Mount Sinai Hospital
Urogynecology Department. Approximately 4 to 6 eligible patients are seen per week and it is
estimated that at least one patient will be recruited per week. The study will be completed
in approximately two years. This will be a single centre study conducted at the Mount Sinai
Hospital, Toronto, Canada.
5- Manoeuvre Study Design This study is a double blind, randomized controlled trial of
patients undergoing transvaginal repair of midline cystocele, with or without concomitant
correction of prolapse in other vaginal compartments, but without correction of stress
incontinence. All the patients will provide written informed consent for participation. At
baseline, all participants will undergo a standardized evaluation, which will include an
urogynecologic history, pelvic organ prolapse quantification examination, and urodynamic
evaluation. The urodynamic evaluation will include measurement of post-void residual urine
volume by catheter and/or ultrasound bladder scan, uroflowmetry, a filling cystometrogram
and urethral pressure profilometry.
Patients will be randomized intraoperatively using computer-based randomization. At the time
of the surgical step of bladder plication, the computer program will be used, and will
indicate whether sutures will be placed or omitted. Trimming of redundant vaginal mucosa
will be performed before randomization to avoid any bias resulting from the amount of mucosa
removed.
Standardized surgical technique
- Midline vaginal mucosal incision
- Sharp surgical dissection between vagina and pubocervical fascia.
- Completion of prolapse repair of vault, rectocele, uterine prolapse.
- Manual reduction of prolapse and trimming of redundant vaginal mucosa.
- Open envelope to determine group of allocation.
- If randomization to plication, place midline interrupted sutures of 0 or 2-0
polyglycolic acid sutures.
- Administer indigo carmine 5 ml IV.
- Cystoscopy with 70º telescopes.
- Close vaginal mucosa with running interlocking 0 or 2-0 polyglycolic sutures.
Protocol On postoperative day 1, patients will have the Foley catheter removed and
measurement of post-void residual urine volume will be done (either by in and out
catheterization, suprapubic ultrasound or via a Bonnano suprapubic catheter).
Catheterization will be continued until residual volumes are less than 200 ml twice in a
row. Registered nurses who will be masked to the treatment assignment will perform the
post-operative assessment and examination.
6- Outcomes Primary Outcome Measures The primary outcome variable will be the requirement
for catheterization beyond postoperative day 2. This has been chosen as the primary outcome
since this would delay the usual hospital discharge on postoperative day 2, thus presenting
a practical problem for patients (important based in our patients value and expectative
after pelvic organ prolapse surgery), physicians, and hospitals (cost).
Other Outcome Measures A secondary outcome will be intraoperative ureteric obstruction. All
patients, regardless of study arm, will undergo intraoperative cystoscopy following
intravenous administration of indigo carmine in order to identify this complication. If this
complication does occur the suspected plicating suture(s) will removed, replaced more
centrally, and cystoscopy repeated to ensure ureteric permeability.
Analysis Sample Size A chart review of patients at the Mount Sinai Hospital, who underwent
typical pelvic floor repair, including transvaginal cystocele repair and mid-urethral sling,
has shown that approximately 50% of patients experience short-term postoperative voiding
dysfunction. In order to provide convincing evidence that there may be a benefit to omitting
plicating sutures, this study will be powered to detect a substantial difference in voiding
dysfunction - from 50% of patients down to 25% of patients. Using a chi-square distribution
and an alpha error of 0.05, the required sample size is 58 patients per group. (SAS 9.2)
Statistical Analysis Statistical analysis will be performed using SAS 9.2 for Windows™.
Chi-square analysis will be used to evaluate categorical variables and T-Tests for
continuous variables.
Data Management The data will be collected into a database. Statistical analysis will be
conducted using SAS 9.2. All data will be kept confidential and protected.
Ethical Issues Written consent will be obtained from each participant. All data will be
anonymous and will only be coded by a participant identification number.
An ethics proposal will be submitted to the Mount Sinai Hospital Research Ethics Board prior
to beginning the recruitment. Patients with questions or concerns are free to contact the
research assistant or a representative from the ethics board for clarification. The contact
information will be noted in the consent form.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05439902 -
Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women
|
N/A | |
Terminated |
NCT00713908 -
Voiding Dysfunction in the Postoperative Period Following Placement of the TVT
|
N/A | |
Completed |
NCT00679315 -
Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female
|
Phase 2 | |
Completed |
NCT04010591 -
The Measurement of Bladder Impedance and Heart Rate During Urodynamic Study
|
||
Completed |
NCT00719589 -
Outcomes of Pudendal InterStim
|
N/A | |
Completed |
NCT01189136 -
Treatment for Acute Postoperative Voiding Dysfunction
|
N/A | |
Completed |
NCT00214045 -
Rigid Versus Flexible Cystoscopy in Women
|
N/A | |
Completed |
NCT05820139 -
Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery
|
N/A | |
Completed |
NCT03574610 -
Brain Targets in Patients With Bladder Emptying Difficulties
|
N/A | |
Recruiting |
NCT00839969 -
Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
|
N/A | |
Completed |
NCT01154946 -
Clinical Implication of DAC (Detrusor After-contraction)
|
N/A | |
Recruiting |
NCT03913819 -
Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction
|
||
Withdrawn |
NCT02297178 -
A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
|
N/A | |
Not yet recruiting |
NCT06404996 -
Smart-phone Application Versus Conventional Paper for the Documentation of Voiding Dysfunction in Children
|
N/A | |
Completed |
NCT05295823 -
Patient Self Measurement of Post-Void Residual Bladder Volume (PVR) Using Ultrasound
|
N/A | |
Active, not recruiting |
NCT02193451 -
Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods
|
N/A | |
Completed |
NCT01228370 -
Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder
|
Phase 4 |